1 / 28

34 Cancer

34 Cancer. Lecture Outline, 11/30/05. Review the Cell cycle Cancer is a genetic disease Oncogenes and proto-oncogenes Normally promote cell growth. Become oncogenic after point mutations, duplications, deletion of silencer, etc Tumor Suppressor genes Normally inhibit cell growth.

rupali
Download Presentation

34 Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 34 Cancer

  2. Lecture Outline, 11/30/05 • Review the Cell cycle • Cancer is a genetic disease • Oncogenes and proto-oncogenes • Normally promote cell growth. • Become oncogenic after point mutations, duplications, deletion of silencer, etc • Tumor Suppressor genes • Normally inhibit cell growth. • Allow cell growth when damaged or deleted. • Mutator genes • The multi-step model of cancer

  3. Cancer is caused by mutant genes • Mutations in regulatory genes lead to uncontrolled cell growth • Understanding gene regulation is one key to understanding cancer • All cancers trace back to single cell • Must accumulate multiple mutations, all in the same cell lineage

  4. Changes in growth properties of cancer cells

  5. The incidence of human cancers increases markedly with age It takes a long time for the causative mutations to accumulate in a cell

  6. The Human Cell Cycle ~ 1 hour ~ 4 hours ~ 10 hours ~ 9 hours

  7. Cell Cycle Regulators and Cancer

  8. Free E2F is a transcription activator Rb represses E2F Cyclin/Cdk inactivates Rb by phosphorylation

  9. P53 is a transcription factor that activates p21, an inhibitor of cyclin/cdk2

  10. Growth factor 1 2 3 1 2 3 5 4 MUTATION (a) Cell cycle–stimulating pathway. Hyperactive Ras protein (product of oncogene) issues signals on its own Ras This pathway is triggered by a growth factor that binds to its receptor in the plasma membrane. The signal is relayed to a G protein called Ras. Like all G proteins, Ras is active when GTP is bound to it. Ras passes the signal to a series of protein kinases. The last kinase activates a transcription activator that turns on one or more genes for proteins that stimulate the cell cycle. If a mutation makes Ras or any other pathway component abnormally active, excessive cell division and cancer may result. 1 G protein GTP 2 3 Ras p p p GTP p p 4 p 5 Protein kinases (phosphorylation cascade) Receptor NUCLEUS Transcription factor (activator) DNA Gene expression Protein that stimulates the cell cycle Protein kinases (b) Cell cycle–inhibiting pathway. In this MUTATION pathway, DNA damage is an intracellular signal that is passed via protein kinases and leads to activation of p53. Activated p53 promotes transcription of the gene for a protein that inhibits the cell cycle. The resulting suppression of cell division ensures that the damaged DNA is not replicated. Mutations causing deficiencies in any pathway component can contribute to the development of cancer. Defective or missing transcription factor, such as p53, cannot activate transcription 1 2 3 UV light Active form of p53 DNA damage in genome DNA Protein that inhibits the cell cycle EFFECTS OF MUTATIONS possibly leading to cancer, can result if the cell cycle is overstimulated, as in (a), or not inhibited when it normally would be, as in (b). (c) Effects of mutations. Increased cell division, Protein overexpressed Protein absent Cell cycle not inhibited Cell cycle overstimulated Increased cell division  Signaling pathways that regulate cell division Figure 19.12

  11. Stimulation versus inhibition of G1 progression Inhibition of G1 progression Stimulation of G1 progression mitogens anti-mitogen (TGF-b) DNA-damage myc ras ? p15 p53 PKB p16 cyclin D / cdk4 p27 p21 cyclin D / cdk4 P P pRB pRB P pRB pRB P P P Inhibition Inhibition S-phase entry S-phase entry S-phase entry S-phase entry allowed allowed oncogenes tumor suppressor genes

  12. Oncogenes • All are involved in positive control of cell growth and division. • About 100 different oncogenes have been identified • Can be various kinds of proteins: • Growth factors, regulatory genes involved in the control of cell multiplication. • Protein kinases, add phosphate groups to target proteins, important in signal transduction pathways. • “Proto-oncogenes” • Normal form of the gene that is involved in positive regulation of the cell cycle

  13. Proto-oncogene DNA Point mutation within a control element Translocation or transposition: gene moved to new locus, under new controls Point mutation within the gene Gene amplification New promoter Oncogene Oncogene Hyperactive or degradation- resistant protein Normal growth-stimulating protein in excess Normal growth-stimulating protein in excess Normal growth-stimulating protein in excess  Genetic changes that can turn proto-oncogenes into oncogenes Figure 19.11

  14. Translocation puts abl under the control of a different promoter

  15. Translocation puts bcl near a new enhancer

  16. Ras Proto-oncogene • Mutated in 30% of all cancers. • A “molecular switch” in the signal transduction pathway leading from growth factors to gene expression controlling cell proliferation: • GF  receptor   Ras    TF  target genes  growth. • A single amino acid change in Ras protein can cause constant stimulation of the pathway, even in the absence of growth factors.

  17. Receptor tyrosine kinases can activate ras ras is a monomeric G-protein “molecular switch” You’ve seen RAS before . . .

  18. Ras activation sets off aphosphorylation cascade Mitogen Activated Protein Kinases MAPKs 10 100 MAPKKK MAPKK 1,000 Controls: -Transcription Factors -Translation Factors -Cell Division MAPK 100,000

  19. PROBLEMS IN CANCER: - broken ras – won’t shut off • Broken receptor – thinks ligand there • even when it isn’t • broken MAPK – on all the time, even when • not phosphorylated RESULT: continuous signal for cell to divide

  20. Oncogenes act cooperatively in tumor-induction

  21. Tumor Suppressor Genes • Normally inhibit cell growth • Example: retinoblastoma • RB protein normally blocks a transcription factor, E2F

  22. p53 Gene • Detects DNA damage • The “Last Gatekeeper” • Involved in 50% of cancers • Often not malignant despite other cancer-causing mutations until p53 is inactivated by mutation. • Two possible responses to DNA damage: • 1) Acts as a Transcription Factor to activate expression of p21, which inhibits CDK/G1 cyclin to halt the cell cycle; then activates DNA repair. • 2) Triggers Apoptosis (programmed cell death) if damage can’t be repaied.

  23. Apoptosis = controlled cell death “executioner” proteins (caspases) break down the cell Reduced cell death can also lead to cancer

  24. Apoptosis pathways http://www.cell-research.com/20014/20014cover.htm

  25. Mutator genes • Cancer is caused by mutations, so factors that increase mutation rate will increase cancer rate. • What kinds of genes would increase mutation rate? • Example: BRCA1 and BRCA2 • Many environmental factors (carcinogens) also cause DNA damage or mutations, that can lead to cancer

  26.  A multistep model for the development of colorectal cancer (1) The clonal origin of tumors: each individual cancer is a clone that arises from a single cell. The progeny cells have growth advantage over the surrounding normal cells. Colon (2) Cancer development is a multi-step process. Multiple mutations accumulated over periods of many years ----“multi-hit” model. 4Loss of tumor-suppressor gene p53 2Activation of Ras oncogene 1Loss of tumor-suppressor gene APC (or other) Colon wall 3Loss of tumor- suppressor gene DCC 5 Additional mutations Larger benign growth (adenoma) Normal colon epithelial cells Small benign growth (polyp) Malignant tumor (carcinoma) Figure 19.13

More Related